IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Buys 26,581 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin purchased 26,581 shares of IRIDEX stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $1.16 per share, with a total value of $30,833.96. Following the completion of the transaction, the insider owned 177,497 shares in the company, valued at approximately $205,896.52. This represents a 17.61% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Price Performance

Shares of IRIX stock opened at $0.88 on Thursday. IRIDEX Corporation has a 1-year low of $0.61 and a 1-year high of $1.65. The stock’s 50-day moving average is $0.73 and its 200 day moving average is $0.95. The company has a market cap of $15.46 million, a P/E ratio of -4.40 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last posted its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The business had revenue of $12.57 million during the quarter, compared to the consensus estimate of $13.59 million. On average, analysts anticipate that IRIDEX Corporation will post -0.12 EPS for the current year.

IRIDEX News Roundup

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Institutional Investors Weigh In On IRIDEX

Several institutional investors have recently added to or reduced their stakes in the business. Weber Capital Management LLC ADV purchased a new stake in shares of IRIDEX during the second quarter worth about $206,616. United Capital Financial Advisors LLC acquired a new stake in IRIDEX in the 2nd quarter worth approximately $41,000. Diversify Advisory Services LLC acquired a new stake in IRIDEX in the 2nd quarter worth approximately $30,000. Diversify Wealth Management LLC acquired a new stake in IRIDEX in the 1st quarter worth approximately $35,000. Finally, Bank of New York Mellon Corp purchased a new stake in IRIDEX during the 2nd quarter worth approximately $29,000. Institutional investors and hedge funds own 20.10% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, IRIDEX has a consensus rating of “Hold” and a consensus target price of $3.00.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.